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COMPARISON OF HEALTHCARE COSTS FOR
REPAGLINIDE, METFORMIN,
REPAGLINIDE/METFORMIN,AND
GLYBURIDE/METFORMIN WITHIN A MANAGED
CARE ORGANIZATION
Stockl K1,Vanderplas A1, Nicklasson L2
1Prescription Solutions, Costa Mesa, CA, USA; 2Novo Nordisk
Pharmaceuticals, Princeton, NJ, USA
OBJECTIVES: To measure healthcare costs for patients
receiving repaglinide, metformin, repaglinide/metformin,
and glyburide/metformin within a managed care organi-
zation (MCO). METHODS: Using retrospective phar-
macy and medical claims from a MCO, adult patients
with type 2 diabetes identiﬁed during CY2000 were strat-
iﬁed into the following cohorts based on their medication
regimen at identiﬁcation date: repaglinide only (n = 500),
metformin only (n = 26,535), repaglinide/metformin 
(n = 172), glyburide/metformin (n = 17,160). Pharmacy,
medical, and total (pharmacy + medical) healthcare costs
were measured for each cohort over a 9-month period.
Costs were adjusted for age, gender, and comorbidities
using Analysis of Covariance. RESULTS: Adjusted phar-
macy costs were lowest for patients receiving metformin
only ($1182; 95% CI $1172–$1191), followed by 
metformin/glyburide ($1339; 95% CI $1327–$1351),
repaglinide only ($1518; 95% CI $1447–$1588), and
repaglinide/metformin ($1936; 95% CI $1816–$2056).
Differences between the cohorts in adjusted medical 
and total healthcare costs were not statistically signiﬁ-
cant. Adjusted medical charges were $6988 for repaglin-
ide/metformin, $8236 for metformin/glyburide, $8267
for metformin only, and $10,392 for repaglinide only.
Total adjusted healthcare costs were lowest for repaglin-
ide/metformin ($8924), followed by metformin only
($9448), metformin/glyburide ($9576), and repaglinide
only ($11,910). CONCLUSIONS: Although not statisti-
cally signiﬁcant, repaglinide/metformin yielded lower
total healthcare costs than metformin alone, met-
formin/glyburide, or repaglinide alone. While these
results need to be conﬁrmed using larger patient popula-
tions, they imply that differences in pharmacy costs of
repaglinide/metformin therapy are offset by measurable
medical cost savings.
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OBJECTIVES: Limited data are available on treatment
cost of diabetes Type 2 patients in Poland. The Cost 
Of Diabetes Type 2 In Poland (CODIP) is a multicenter,
bottom-up designed, retrospective study aimed at evalu-
ation of total cost of diabetes type 2 in Poland. Prelimi-
nary data on direct cost are presented. METHODS:
Patients diagnosed with type 2 diabetes mellitus were ran-
domly selected from outpatients’ charts databases and
surveyed with CODE-2 trial questionnaires adjusted to
Polish setting. Both patient and practitioner question-
naires collected data from each patient on: clinical char-
acteristic, medical and other resources used, quality of
life. Total treatment costs were calculated using drug
retail and medical procedures prices. Values are expressed
in USD value (PPP¢2001 1 PLN = 1,98). RESULTS: 303
patients from 24 centers were included. Mean age 61.0
(95% CI: 59.8; 62.2); time from diagnosis 10.9 (10.0;
11.7); 74.6% patients presented comorbidities with coro-
nary arteries disease as most prevalent (20.5%). The total
annual treatment costs amounted to 4390 PLN (2127
USD). The cost structure: 13.7% physicians consulta-
tions, 2.2% paramedics, 25.6% diabetic drug costs
(insulin 62.8%, oral hypoglycemic agents and glucagon
37.2%), hospital costs 35.7%, emergency service 0.6%.
CONCLUSIONS: Economic impact of diabetes Type 2 in
Poland is considerable. Insulin prescription patterns are
responsible for large part of drug costs.
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The NAVIGATOR trial will evaluate the impact of
nateglinide and valsartan on the progression to diabetes
in subjects with impaired glucose tolerance at risk for 
cardiovascular events. It is well documented that physi-
cian/site characteristics inﬂuence outcomes and resource
utilization in health economic analyses. However, these
characteristics are usually unknown in the international
clinical trial setting. OBJECTIVES: We developed an
approach to proﬁle investigators and sites in multina-
tional clinical trials by administering a survey during the
site recruitment phase of the NAVIGATOR trial. We
hypothesized that characteristics would vary geographi-
cally. METHODS: Survey items were developed based on
a literature review and clinicians’ input. Simple statistics
were used to describe the sample. ANOVA and c2 tests
were used to test for differences across geographic
regions. RESULTS: We received 528 investigator surveys
representing a response rate of 60% and 96% for US and
non-US countries, respectively. Eighty percent of investi-
gators were male and the mean age was 48 years. Forty
percent were endocrinologists, 39% internists, and 20%
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cardiologists. Eighty-ﬁve percent of investigators were
afﬁliated with hospitals with over 101 beds. Sixty-ﬁve
percent and 72% of sites were public and teaching hos-
pitals, respectively. We found signiﬁcant variation among
physician/site characteristics across geographic regions.
Sixteen percent of US respondents were cardiologists,
52% in Latin America, 26% in Eastern Europe, 7% in
Europe, 4% in Africa and Asia Paciﬁc, and 0% in Canada
(p = <.0001). Twenty-nine percent of US investigators
were afﬁliated with public hospitals as compared to
100% in Canada, 97% in Eastern Europe, 88% in
Europe, 87% in Asia Paciﬁc, 53% in Latin America, and
22% in Africa (p = <.0001). CONCLUSION: We assessed
physician/site characteristics in a clinical trial setting and
determined that characteristics vary by geographic region.
Therefore, it is important to measure physician and site
characteristics to avoid the potential for confounding in
the economic evaluation of the NAVIGATOR trial.
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FACTORS INFLUENCING THE DIAGNOSTIC
TESTS PRESCRIBING FOR TYPE 2 DIABETES IN
AMBULATORY PATIENTS 
Rahman AM
St. John’s University, Jamaica, NY, USA
OBJECTIVES: Type 2 Diabetes is associated with severe
complications such as heart disease, stroke, high blood
pressure, kidney disease etc. Approximately 17 million
people suffer from diabetes accounting to 6.2% of the
population in the United States. According to the 
American Diabetes Association, the total cost of diabetes
to the society is 98 billion dollars. Type 2 diabetes
accounts for about 90–95% of all the diagnosed cases of
diabetes. This study examines the various physician and
patient factors, which inﬂuence the diagnostic test pre-
scribing for diabetes in ambulatory patients. METHODS:
Patient factors such as age, sex, race, geographical loca-
tion and payment source and Physician factors such as
specialty, geographic location and referral status were
used to determine their inﬂuence on the number of diag-
nostic tests prescribed. Data from the National Ambula-
tory Medical Care Survey (NAMCS) 2000 were utilized.
Patients with principal diagnosis of type 2 diabetes (ICD-
9-CM code 250.00) were analyzed using multiple linear
and binomial logit regression models. RESULTS: The
numbers of diagnostic tests performed were independent
of patients’ age, sex and geographic region (R2 = 0.117).
Blacks and Hispanic patients were prescribed more diag-
nostic tests compared to other races (R2 = 0.346).
Patients with Federal source of payments (Medicaid and
Medicare) were prescribed more diagnostic tests than
other patients (R2 = 0.245). Numbers of diagnostic tests
were not inﬂuenced by whether the patient was referred
(R2 = 0.037). Various physician specialties also had no
inﬂuence on the number of diagnostic tests prescribed (R2
= 0.054). CONCLUSIONS: The numbers of diagnostic
tests prescribed are signiﬁcantly inﬂuenced by patients’
race and source of payments. Diagnostic tests constitute
a signiﬁcant portion of the cost of diabetes therapy.
Further research, reviewing the causes of the signiﬁcant
differences seen in this study would help control/reduce
the cost of diabetes therapy.
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OBJECTIVES: A pharmacoeconomic analysis was
carried out comparing a long-acting analog of human
insulin, insulin glargine (once-daily injection), and NPH
human insulin (twice-daily injections) in patients with
Type 1 (DM1) and Type 2 (DM2) diabetes mellitus in
Spain. METHODS: Retrospective analysis using a cost-
offset model, from the perspective of the National Health
System in Spain. The following short term (1 year) health
costs of diabetes mellitus were used in the model: glargine
or NPH insulin treatment, use of lispro insulin, nurse
home visits, severe hypoglycemia episodes, test strips for
glucose control and disposable needles. The utilisation of
resources was estimated from two clinical trials compar-
ing insulin glargine (Lantus) and NPH human insulin in
patients with DM1 and DM2 and from Spanish sources,
and the unit costs from a Spanish health costs database.
RESULTS: The use of glargine insulin instead of NPH
insulin would result in an annual saving of €234.75 and
€89.47 for a patient with DM1 and DM2, respectively.
Although the acquisition cost of glargine insulin is higher,
yearly savings can be achieved compared to NPH insulin
in the remaining costs analysed especially in the use of
less test strips (€198.85 in DM1 and DM2), less costs in
nurse home visits (€83.22 in DM1 and DM2), lower
doses of lispro insulin (€49.78 in DM1), lower incidence
of severe hypoglycemia (€6.91 and €1.33 in DM1 and
DM2) and lower costs in insulin needles (5.02 euros in
DM1 and DM2). CONCLUSIONS: A comprehensive
analysis of the costs associated with insulin treatment
shows that switching to once-daily insulin glargine from
NPH insulin reduces Health System costs for treating
Type 1 and Type 2 diabetic patients in Spain.
DIABETES—Quality of Life/Preference Based
Outcomes
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EVALUATION OF QUALITY OF LIFE IN
PATIENTS WITH NEUROPATHY USING THE
NORFOLK QUALITY OF LIFE (QOL) TOOL
Vinik EJ, Stansberry KB, Ruck SM,Vinik AI
EVMS, NORFOLK,VA, USA
OBJECTIVE: Our objective was to examine the scores
and reproducibility of a 47 item Quality Of Life ques-
